Table 1 Clinical heterogeneity: PROWESS versus PROWESS-SHOCK - trial characteristics
Trial characteristic | Trial | Proportion with characteristic | Comparison P-value |
|---|---|---|---|
Enrolled in North America | PROWESS | 54.7% | P < 0.0001 |
| Â | PROWESS-SHOCK | 14.1% | Â |
Chronic obstructive pulmonary disease | PROWESS | 24.1% | P < 0.0001 |
| Â | PROWESS-SHOCK | 15.5% | Â |
Lung as site of infection | PROWESS | 53.6% | P < 0.0001 |
| Â | PROWESS-SHOCK | 43.9% | Â |
Presence of shock | PROWESS | 71% | P < 0.0001 |
| Â | PROWESS-SHOCK | 100% | Â |
S. pneumoniae infections | PROWESS | 11.9% | P < 0.0001 |
| Â | PROWESS-SHOCK | 4.5% | Â |
S. aureus infections | PROWESS | 14.3% | P < 0.0001 |
| Â | PROWESS-SHOCK | 3.7% | Â |
Escherichia coli infections | PROWESS | 16.5% | P < 0.0001 |
| Â | PROWESS-SHOCK | 10.3% | Â |
Klebsiella spp. Infections | PROWESS | 6.2% | P < 0.0001 |
| Â | PROWESS-SHOCK | 2.2% | Â |
Use of appropriate antibiotics | PROWESS | 91.2% | P < 0.0001 |
| Â | PROWESS-SHOCK | 84.2% | Â |
Use of steroids for septic shock | PROWESS | 13.5% | P < 0.0001 |
| Â | PROWESS-SHOCK | 49.5% | Â |
Use of heparin | PROWESS | 75.2% | P < 0.0001 |
| Â | PROWESS-SHOCK | 44.7% | Â |
Serious bleeding with drotrecogin | PROWESS | 3.5% | P = 0.0017 |
| Â | PROWESS-SHOCK | 1.2% | Â |